



Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS January 2023

Forward-Looking Statements



This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates and combinations; the potential of TIGIT to be the next advance in cancer treatment; the potential of our biomarker to guide patient selection; our clinical plans and expected timelines, including the expectation to make significant progress in 2023 and that EOS-984 will enter into the clinic in mid-2023; our potential market opportunities; the potential benefits of our collaboration with GSK, including dostarlimab being the ideal combination partner for EOS-448; the potential to differentiate EOS-448 to win with the quality of our therapies, major indications and unique combinations; the expectation that 2023 will be a pivotal year for TIGIT and iTeos being ideally positioned to enter this year; and our expected cash runway into 2026.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos' control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient to support regulatory approval; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos' control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in iTeos' Quarterly Report on Form 10-Q for the nine months ended September 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets.

Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.



Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS January 2023

iTeos well positioned to deliver better drugs to patients



3

Clinical drug
candidates
in 2023

11

Clinical studies
planned or ongoing



\$752M*

Cash balance to fund
development into 2026

68k

Patients diagnosed each year in US for indications
currently in development

\$2B

Partnership with unique
development possibilities




10

Years of expertise in
tumor immunology


* As of September 30, 2022

We build better drugs for people with cancer



EOS-448:
**Anti-TIGIT optimized for
immune cell activation**

Expansive and unique development
plan with GSK



Inupadenant & EOS-984:
**Designed to fully exploit
the adenosine pathway**

Leverage deep understanding of the
adenosine pathway with a focused
clinical plan

Expansive and differentiated development pipeline expected to make significant progress over 2023



Discovery

Preclinical

Phase 1

Phase 2

Phase 3

EOS-448: IgG1 antibody targeting TIGIT



+ dostarlimab | 1L NSCLC PDL1^{high} *

+ dostarlimab | 1L NSCLC PDL1^{high}

+ dostarlimab | 1L HNSCC PDL1^{high/low}

+ dostarlimab + chemotherapy | 1L mNSCLC

+ dostarlimab + CD96 | Advanced Malignancies

+ dostarlimab + PVRIG | Advanced Malignancies

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

Inupadenant: Small molecule targeting A_{2A} receptor



Monotherapy | High Biomarker

+ pembrolizumab | PD-1 Resistant Melanoma

+ chemotherapy | Post-IO Chemo-naïve NSCLC

EOS-984: Small molecule targeting novel mechanism in adenosine pathway



Monotherapy | Advanced Malignancies *

EOS-448 / GSK4428859A

iTeos and GSK are positioned to leverage the TIGIT/CD226 axis

iTeos ideally positioned entering a defining year for TIGIT



Why TIGIT

Validated target in two randomized trials with broad potential.

Why EOS-448

Antibody optimized to activate multiple types of immune cells.


Why iTeos & GSK

\$2B collaboration enabling a differentiated and expansive clinical development plan with unique and rational combinations.


Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response




Maximize activity by leveraging both ends of antibody



Antibody design translates into preclinical differentiation



Antibody design translates to reduction in immunosuppressive cells in patient tumors




EOS-448 monotherapy mediates 2- to 4- fold reduction of tumor infiltrating TIGIT+ Tregs cells

GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448



Dostarlimab has proven activity in lung, rectal and endometrial cancers

Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab




PERLA Study (PFS data above): Randomized, double blind phase 2 trial of 1L treatment for metastatic non-squamous NSCLC (N=243)


First wave of development underway in large indications



EOS-448: IgG1 antibody targeting TIGIT



U.S. annual incidence



Source: Kantar, iTeos internal analysis

Clinical strategy: Differentiating to win

1. Leveraging high-quality doublet with dostarlimab in major indications
2. Additional novel doublets beyond PD-1
3. Unique triplets expanding opportunities

Adenosine pathway

iTeos has developed a unique approach to unlock this important immunosuppressive pathway

Leveraging unique understanding of adenosine pathway to realize full potential



Why Adenosine Pathway

Major mechanism of immunosuppression with recent clinical validation.

Why Inupadenant

Uniquely designed for activity in solid tumors.

Why iTeos


Deep understanding of the adenosine pathway leading to potential patient selection biomarkers.

Identification of new target: First-in-class EOS-984 entering clinic.

Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors




Very high concentrations of adenosine in multiple tumor types



Human primary tumor resections; Adenosine quantified by quantitative mass-spec imaging (QMSI)

Insurmountable, highly selective $A_{2A}R$ antagonist




Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection



RECIST-evaluable patients (N=38)

*Progression-Free >6 Months



Presented at the ASCO 2021 Annual Meeting

Biomarker case study

Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date

Tumor: Adenocarcinoma of unknown origin

Prior progression on three lines: radiation, chemotherapy and PD-1

Target lesion	Baseline	1 st scan	2 nd scan
Subcarinal lymph node	15	14	11
Right hilar lymph node	15	15	10
% Reduction		3%	30%

iteos Therapeutics internal data

Leveraging our unique knowledge of adenosine pathway with focused investment



Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Inupadenant: Small molecule targeting A_{2A} receptor

Monotherapy | High Biomarker

+ pembrolizumab | PD-1 Resistant Melanoma

+ chemotherapy | Post-IO Chemo-naïve NSCLC

EOS-984: Small molecule targeting a new mechanism in adenosine pathway

Monotherapy | Advanced Malignancies *


Clinical strategy:

1. Focused development of inupadenant in post-IO chemo-naïve NSCLC
2. Further evaluation of predictive biomarker
3. First-in-class program (EOS-984) entering clinic

iTeos' Mission: We Build Better Drugs

2023 Outlook:

- Pivotal year for TIGIT
- EOS-448: Optimized active TIGIT antibody with unique development plans
- Inupadenant & EOS-984: Designed to exploit the adenosine pathway



iTEOS
THERAPEUTICS

Thank You

Nasdaq: ITOS January 2023